Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

@article{Jones2012EfficacyAS,
  title={Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.},
  author={Paul W. Jones and Dave Singh and Eric D Bateman and Alvar Agusti and Rosa Lamarca and Gonzalo de Miquel and Rosa Maria Segarra and Cynthia F Caracta and Esther Garcia Gil},
  journal={The European respiratory journal},
  year={2012},
  volume={40 4},
  pages={830-6}
}
  • Paul W. Jones, Dave Singh, +6 authors Esther Garcia Gil
  • Published 2012 in The European respiratory journal
The efficacy and safety of two doses of aclidinium bromide were evaluated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). In this 24-week, double-blind trial, patients were randomised to twice-daily aclidinium (200 μg or 400 μg) or placebo. The primary efficacy end-point was change in trough forced expiratory volume in 1 s (FEV(1)) at week 24. Other end-points included peak FEV(1), health status (St George's Respiratory Questionnaire; SGRQ) and dyspnoea… CONTINUE READING
71 Extracted Citations
17 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 71 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 17 references

Similar Papers

Loading similar papers…